Header Logo

Connection

Usman Baber to Acute Coronary Syndrome

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Acute Coronary Syndrome.
Usman Baber
Connection Strength
11.572
Acute Coronary Syndrome
  1. Switching Between Intravenous and Oral P2Y12 Inhibition: Easier Said Than Done. JACC Cardiovasc Interv. 2023 01 09; 16(1):47-49.
    View in: PubMed
    Score: 0.784
  2. Extending the aspirin-free paradigm to patients with acute coronary syndrome: is it time to change guidelines? EuroIntervention. 2020 Oct 23; 16(8):620-622.
    View in: PubMed
    Score: 0.673
  3. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020 10 01; 41(37):3533-3545.
    View in: PubMed
    Score: 0.670
  4. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004945.
    View in: PubMed
    Score: 0.594
  5. Reply: Chronic Kidney Disease and Antiplatelet Therapy: A Worrying Gap Between Evidence Based Medicine and Clinical Practice. JACC Cardiovasc Interv. 2018 02 12; 11(3):320.
    View in: PubMed
    Score: 0.558
  6. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC Cardiovasc Interv. 2017 10 23; 10(20):2017-2025.
    View in: PubMed
    Score: 0.538
  7. Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. Am Heart J. 2017 Jun; 188:73-81.
    View in: PubMed
    Score: 0.522
  8. Reply: Risk Scores From PARIS Registry: Are They Useful in a Contemporary Cohort of ACS Patients? J Am Coll Cardiol. 2016 11 29; 68(21):2392-2393.
    View in: PubMed
    Score: 0.514
  9. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. Am Heart J. 2016 Dec; 182:125-134.
    View in: PubMed
    Score: 0.508
  10. Patients with chronic kidney disease/diabetes mellitus: the high-risk profile in acute coronary syndrome. Curr Cardiol Rep. 2013 Aug; 15(8):386.
    View in: PubMed
    Score: 0.408
  11. Is there attenuation of benefit of invasive therapy in patients with chronic kidney disease? Results from randomized trials and registry data. Curr Cardiol Rep. 2012 Aug; 14(4):521-7.
    View in: PubMed
    Score: 0.380
  12. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc Imaging. 2012 Mar; 5(3 Suppl):S53-61.
    View in: PubMed
    Score: 0.370
  13. Acute coronary syndromes: Antithrombotics in ACS--moving beyond unfractionated heparin. Nat Rev Cardiol. 2011 Sep 27; 8(11):613-4.
    View in: PubMed
    Score: 0.359
  14. How serious a problem is bleeding in patients with acute coronary syndromes? Curr Cardiol Rep. 2011 Aug; 13(4):312-9.
    View in: PubMed
    Score: 0.355
  15. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024 Sep 07; 404(10456):937-948.
    View in: PubMed
    Score: 0.220
  16. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome. Circulation. 2024 Jul 23; 150(4):317-335.
    View in: PubMed
    Score: 0.218
  17. Reply: Decoding Ticagrelor Dyspnea: Central Apnea Screening Before Drug Discontinuation. JACC Cardiovasc Interv. 2024 Feb 12; 17(3):452-453.
    View in: PubMed
    Score: 0.212
  18. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium. Circulation. 2023 06 20; 147(25):1933-1944.
    View in: PubMed
    Score: 0.202
  19. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022 08 11; 8(5):492-502.
    View in: PubMed
    Score: 0.191
  20. Comparison of the effect of Morphine and Fentanyl in patients with acute coronary syndrome receiving Ticagrelor - The COMET (Comparison Morphine, Fentayl and Ticagrelor) randomized controlled trial. Int J Cardiol. 2021 05 01; 330:1-6.
    View in: PubMed
    Score: 0.172
  21. One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. Cardiovasc Drugs Ther. 2021 04; 35(2):309-320.
    View in: PubMed
    Score: 0.171
  22. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clin Res Cardiol. 2020 Jun; 109(6):725-734.
    View in: PubMed
    Score: 0.159
  23. Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. J Thromb Thrombolysis. 2019 Jul; 48(1):42-51.
    View in: PubMed
    Score: 0.154
  24. Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2020 04 01; 95(5):885-892.
    View in: PubMed
    Score: 0.153
  25. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheter Cardiovasc Interv. 2019 Jul 01; 94(1):53-60.
    View in: PubMed
    Score: 0.149
  26. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Am J Cardiol. 2019 03 01; 123(5):709-716.
    View in: PubMed
    Score: 0.148
  27. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. Int J Cardiol. 2019 Jan 15; 275:31-35.
    View in: PubMed
    Score: 0.146
  28. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2019 02 15; 93(3):E112-E119.
    View in: PubMed
    Score: 0.146
  29. Predicting risk for bleeding after PCI: Another step in the right direction but work remains. Int J Cardiol. 2018 03 01; 254:45-46.
    View in: PubMed
    Score: 0.139
  30. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Can J Cardiol. 2018 03; 34(3):319-329.
    View in: PubMed
    Score: 0.138
  31. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2018 01 08; 11(1):68-76.
    View in: PubMed
    Score: 0.138
  32. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.135
  33. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol. 2017 08 01; 2(8):855-862.
    View in: PubMed
    Score: 0.135
  34. Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor. Circ Cardiovasc Interv. 2017 08; 10(8).
    View in: PubMed
    Score: 0.135
  35. Antiplatelet treatments: recent evidence from randomized controlled trials. Curr Opin Cardiol. 2017 Jul; 32(4):356-362.
    View in: PubMed
    Score: 0.134
  36. Anemia and Acute Coronary Syndrome: Time for Intervention Studies. J Am Heart Assoc. 2016 11 19; 5(11).
    View in: PubMed
    Score: 0.128
  37. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Catheter Cardiovasc Interv. 2017 Mar 01; 89(4):629-637.
    View in: PubMed
    Score: 0.124
  38. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016 May 17; 67(19):2224-2234.
    View in: PubMed
    Score: 0.123
  39. Meta-Analysis of Radial Versus Femoral Access for Percutaneous Coronary Interventions in Non-ST-Segment Elevation Acute Coronary Syndrome. Am J Cardiol. 2016 Jan 15; 117(2):172-8.
    View in: PubMed
    Score: 0.119
  40. Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. Am Heart J. 2016 Jan; 171(1):40-7.
    View in: PubMed
    Score: 0.117
  41. Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome? Curr Opin Cardiol. 2014 Jul; 29(4):301-6.
    View in: PubMed
    Score: 0.109
  42. A comparison of coronary CTA and stress testing using high-efficiency SPECT MPI for the evaluation of chest pain in the emergency department. J Nucl Cardiol. 2014 Apr; 21(2):305-18.
    View in: PubMed
    Score: 0.104
  43. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial. Circ Cardiovasc Interv. 2012 Apr; 5(2):157-65.
    View in: PubMed
    Score: 0.092
  44. Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials. Circ Cardiovasc Interv. 2015 Aug; 8(8):e002475.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.